Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will unveil its latest earnings on Monday, July 25, 2011. Neurocrine Biosciences, Inc. discovers, develops and plans to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 6 cents per share, a swing from a loss of 9 cents in the year earlier quarter. During the past three months, the average estimate has moved down from 7 cents. Between one and three months ago, the average estimate moved down, but it has been unchanged at 6 cents during the last month. For the year, analysts are projecting net income of 65 cents per share, a swing from net loss of 16 cents last year.

Past Earnings Performance: The company met estimates last quarter after beating the forecasts in the prior two. In the first quarter, the company reported profit of 5 cents per share versus a mean estimate of net income of 5 cents per share. In the fourth quarter of the last fiscal year, the company beat estimates by 0 cents.

Savvy Investing Tip: Our CHEAT SHEET investing framework recommends only stocks with two straight quarters of earnings growth. Learn More >>

Wall St. Revenue Expectations: On average, analysts predict $13.3 million in revenue this quarter, a rise of more than twofold from the year ago quarter. Analysts are forecasting total revenue of $77.8 million for the year, a rise of more than twofold from last year’s revenue of $33.5 million.

Analyst Ratings: Analysts are bullish on this stock with six analysts rating it as a buy, none rating it as a sell and three rating it as a hold.

Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Abbott Laboratories (NYSE:ABT), Repligen Corporation (NASDAQ:RGEN), Pfizer Inc. (NYSE:PFE), EntreMed, Inc. (NASDAQ:ENMD), Johnson & Johnson (NYSE:JNJ), Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT), BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), Forest Laboratories, Inc. (NYSE:FRX), and Repros Therapeutics Inc. (NASDAQ:RPRX).

Stock Price Performance: During May 20, 2011 to July 19, 2011, the stock price had risen 78 cents (11%) from $7.07 to $7.85. The stock price saw one of its best stretches over the last year between March 22, 2011 and March 31, 2011 when shares rose for eight-straight days, rising 15.3% (+$1.01) over that span. It saw one of its worst periods between July 7, 2011 and July 19, 2011 when shares fell for nine-straight days, falling 7% (-59 cents) over that span. Shares are up 21 cents (+2.7%) year to date.

(Source: Xignite Financials)

Get Actionable Investing Insights: Check Out Wall St. Cheat Sheet’s newest Feature Trades of the Month!

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!